Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The JNK signaling pathway against titanium-particle-induced osteoclastogenesis and bone resorption in vivo.

European review for medical and pharmacological sciences·2023
Same author

A low-cost edge AI-chip-based system for real-time algae species classification and HAB prediction.

Water research·2023
Same author

Characteristics of US military personnel with atrial fibrillation and associated deployment and retention rates.

BMJ military health·2021
Same author

Trabecular microstructure is influenced by race and sex in Black and White young adults.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2018
Same author

Oral chronic GVHD outcomes and resource utilization: a subanalysis from the chronic GVHD consortium.

Oral diseases·2015
Same author

Functions of neurofilaments in synapses.

Molecular psychiatry·2015

Related Experiment Video

Updated: Jul 19, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.

R T O'Donnell1, S J DeNardo, A Yuan

  • 1Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis Medical Center, Sacramento, California 95816, USA.rtodonnell@ucdavis.edu

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 19, 2001
PubMed
Summary

This Phase I study of radioimmunotherapy (RIT) with (111)In/(90)Y-2IT-BAD-m170 found it well-tolerated in metastatic prostate cancer patients. The treatment targeted cancer effectively and provided temporary pain relief, establishing a maximum tolerated dose.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jul 19, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Immunotherapy

Background:

  • Androgen-independent metastatic prostate cancer (mPC) presents a significant unmet need, with over 31,000 annual deaths in the US.
  • Novel therapeutic strategies beyond hormonal manipulation are crucial for treating mPC, focusing on its unique biochemical and molecular profiles.
  • Radioimmunotherapy (RIT) offers a targeted approach, utilizing tumor-specific monoclonal antibodies to deliver localized radiation therapy.

Purpose of the Study:

  • To determine the toxicity and maximum tolerated dose (MTD) of (111)In-2IT-BAD-m170 (imaging) and (90)Y-2IT-BAD-m170 (therapy).
  • To assess the specificity of these agents in targeting metastatic prostate cancer.
  • To evaluate the efficacy of (90)Y-2IT-BAD-m170 in palliating pain associated with metastatic prostate cancer.

Main Methods:

  • A Phase I clinical trial involving patients with androgen-independent mPC and adequate organ function.
  • Dosimetry and pharmacokinetics were evaluated using (111)In-2IT-BAD-m170 prior to therapy.
  • Single doses of (90)Y-2IT-BAD-m170 were administered at escalating levels (0.185 to 0.740 GBq/m(2)) to cohorts of three patients.
  • Pain and prostate-specific antigen (PSA) levels were monitored post-therapy.

Main Results:

  • The MTD of (90)Y-2IT-BAD-m170 was established at 0.740 GBq/m(2) for patients with limited axial skeletal involvement.
  • Toxicity was primarily reversible myelosuppression.
  • (111)In-2IT-BAD-m170 successfully targeted metastatic prostate cancer in all 17 patients.
  • Significant radiation doses were delivered to bone and nodal metastases.
  • Seven of thirteen patients experiencing pain reported partial or complete pain resolution lasting an average of 4.3 weeks.

Conclusions:

  • The study successfully determined the MTD for (111)In/(90)Y-2IT-BAD-m170 in patients with metastatic prostate cancer.
  • The RIT agents were well-tolerated, demonstrating specific targeting of metastases.
  • (111)In/(90)Y-2IT-BAD-m170 showed potential for temporary pain palliation in metastatic prostate cancer.